TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06824467: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-bas

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 770 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06824467 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06824467 Rescue Dossier →